4 unknown. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 4 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB) Mirabegron 50 MG, Oxybutynin Chloride 5 MG - Overactive Bladder | Phase 2 | Unknown | Seoul National University Hospital | 44 | 2024-04-01 | 2024-03-08 |
| Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children Beta3-Agonists, Adrenergic, Anticholinergic drug, Solifenacin - Voiding Disorders, Overactive Bladder | Phase 1 / Phase 2 | Unknown | Mansoura University | 70 | 2022-02-01 | 2022-02-15 |
| NOGO for an Overactive Bladder extract from Angelica archangelica leaf, Placebo - Overactive Bladder, Nocturia | Phase 2 | Unknown | SagaNatura | 200 | 2020-05-01 | 2020-11-12 |
| This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo. Botox - Overactive Bladder | Phase 2 / Phase 3 | Unknown | Urological Sciences Research Foundation | 40 | 2007-01-01 | 2007-05-30 |
Urinary Bladder, Overactive (4) · Nocturia (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Lower Urinary Tract Symptoms (4) · Male Urogenital Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Urinary Bladder Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Urological Manifestations (4)
Adrenergic beta-3 Receptor Agonists (1) · Botulinum Toxins, Type A (1) · Cholinergic Antagonists (1) · Solifenacin Succinate (1) · mirabegron (1) · oxybutynin (1)
Mansoura University (1) · SagaNatura (1) · Seoul National University Hospital (1) · Urological Sciences Research Foundation (1)
South Korea (1) · Spain (1) · United States (1)
Islam Mansour, Mb ChB (1) · Kwanjin Park, MD/PhD (1) · Leonard S Marks, M.D. (1) · Marcela Gonzalez-Gross, Ph.D. (1)